Skip to main content
Clinical Trials/NCT03566745
NCT03566745
Unknown
Not Applicable

Elucidating the Molecular and Biochemical Basis of the Human AhR-mutation Disease

Hillel Yaffe Medical Center0 sites14 target enrollmentJuly 1, 2018
ConditionsMutation, Point

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mutation, Point
Sponsor
Hillel Yaffe Medical Center
Enrollment
14
Primary Endpoint
Low protein activity
Last Updated
7 years ago

Overview

Brief Summary

In a previous study, we have identified a consanguineous family from Northern Israel with three children affected by idiopathic infantile nystagmus (IIN) and foveal hypoplasia, which follow an autosomal recessive mode of inheritance of AhR gene. in this study we will determine whether the disease phenotype is the consequence of a decrease in or absence of AHR-induced AHH activity

Detailed Description

In a previous study, we have identified a consanguineous family from Northern Israel with three children affected by idiopathic infantile nystagmus (IIN) and foveal hypoplasia, which follow an autosomal recessive mode of inheritance of AhR gene. in this study we will: 1. To determine whether the disease phenotype is the consequence of a decrease in or absence of AHR-induced AHH activity. To this end, basal and ligand-mediated AHH enzyme activity will be compared in heterozygotic and homozygotic family members versus healthy volunteers. 2. To examine steady state protein levels of the AHR protein in cells of homo- and heterozygotic patients versus those of healthy volunteers. If no mutant protein is detected, we will determine the effect of the mutation on mRNA stability. 3. To analyze steady state levels of related partner proteins (such as ANRT) and proteins levels of transcriptional targets (AHH) in heterozygotic and homozygotic family members versus healthy volunteers. 4. To investigate the ability of the mutant allele to induce transcriptional activation in an engineered yeast test system. We will use a yeast strain engineered to contain human AHR and AHR nuclear translocator together with a reporter gene to investigate whether the mutation interferes with transcription activation.

Registry
clinicaltrials.gov
Start Date
July 1, 2018
End Date
November 30, 2019
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Muhammad Mahajnah

Head, Institute of pediatric neurology

Hillel Yaffe Medical Center

Eligibility Criteria

Inclusion Criteria

  • patients with mutation in AhR gene

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Low protein activity

Time Frame: 1 year

Low protein activity

Similar Trials